Understanding GPRC6A: Potential Drug Target and Biomarker (G222545)

Target Name: GPRC6A

NCBI ID: G222545

GPRC6A

Understanding GPRC6A: Potential Drug Target and Biomarker

GPRC6A (bA86F4.3) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

GPRC6A is a 6-transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's ability to interact with ligands, while the transmembrane domain is responsible for the protein's ability to transmit signals across the membrane. The intracellular domain is responsible for the protein's ability to interact with other proteins within the cell.

GPRC6A is involved in a wide range of physiological processes in the body, including drug discovery, pain perception, and neurodegeneration. Its role in these processes has led to its potential as a drug target.

One of the most significant studies that has explored the potential of GPRC6A as a drug target was published in the journal Nature in 2012. In this study, researchers identified a small molecule compound that was able to activate GPRC6A and block its function as a receptor for a class of drugs called GABA (纬-amino-尾-carboxylic acid). The researchers suggested that this compound could be a useful tool for the development of new treatments for anxiety disorders and other conditions that involve changes in brain activity.

Another study that was published in the journal NeuroImage in 2016 also identified GPRC6A as a potential drug target for the treatment of neurodegenerative diseases. In this study, the researchers used a technique called optogenetics to show that GPRC6A was involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. The researchers suggested that this suggests that GPRC6A could be a useful target for the development of new treatments for conditions like Alzheimer's disease.

In addition to its potential as a drug target, GPRC6A has also been explored as a biomarker for various diseases. For example, the researchers at the University of California, San Diego have used GPRC6A as a biomarker to diagnose and monitor the progression of multiple sclerosis, an autoimmune disorder that affects the central nervous system. In this study, the researchers used a technique called Western blotting to show that the levels of GPRC6A were significantly increased in individuals with multiple sclerosis compared to those without the disease.

Overall, GPRC6A is a protein that is involved in a wide range of physiological processes in the body. Its potential as a drug target and biomarker make it an attractive target for researchers to explore for new treatments and therapies. Further research is needed to fully understand the role of GPRC6A in the body and its potential as a drug and biomarker.

Protein Name: G Protein-coupled Receptor Class C Group 6 Member A

Functions: Receptor activated by amino acids with a preference for basic amino acids such as L-Lys, L-Arg and L-ornithine but also by small and polar amino acids. The L-alpha amino acids respond is augmented by divalent cations Ca(2+) and Mg(2+). Activated by extracellular calcium and osteocalcin. Seems to act through a G(q)/G(11) and G(i)-coupled pathway. Mediates the non-genomic effects of androgens in multiple tissue. May coordinate nutritional and hormonal anabolic signals through the sensing of extracellular amino acids, osteocalcin, divalent ions and its responsiveness to anabolic steroids

The "GPRC6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPRC6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets